- Home
- PSO vs DVA Comparison
PSO vs DVA Comparison
Compare PSO & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSO
- DVA
- Stock Information
- Founded
- PSO 1844
- DVA 1994
- Country
- PSO United Kingdom
- DVA United States
- Employees
- PSO N/A
- DVA N/A
- Industry
- PSO Books
- DVA Misc Health and Biotechnology Services
- Sector
- PSO Consumer Discretionary
- DVA Health Care
- Exchange
- PSO Nasdaq
- DVA Nasdaq
- Market Cap
- PSO 8.4B
- DVA 9.4B
- IPO Year
- PSO 2000
- DVA 1995
- Fundamental
- Price
- PSO $13.06
- DVA $120.45
- Analyst Decision
- PSO
- DVA Hold
- Analyst Count
- PSO 0
- DVA 4
- Target Price
- PSO N/A
- DVA $145.00
- AVG Volume (30 Days)
- PSO 769.8K
- DVA 1.2M
- Earning Date
- PSO 01-01-0001
- DVA 10-29-2025
- Dividend Yield
- PSO 2.51%
- DVA N/A
- EPS Growth
- PSO 31.65
- DVA 5.63
- EPS
- PSO 0.90
- DVA 9.76
- Revenue
- PSO $4,822,578,436.00
- DVA $13,317,965,000.00
- Revenue This Year
- PSO $2.17
- DVA $6.24
- Revenue Next Year
- PSO $5.10
- DVA $3.32
- P/E Ratio
- PSO $13.74
- DVA $12.30
- Revenue Growth
- PSO N/A
- DVA 5.14
- 52 Week Low
- PSO $12.85
- DVA $113.97
- 52 Week High
- PSO $17.90
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- PSO 36.57
- DVA 46.93
- Support Level
- PSO $12.95
- DVA $113.97
- Resistance Level
- PSO $13.17
- DVA $122.26
- Average True Range (ATR)
- PSO 0.15
- DVA 3.12
- MACD
- PSO 0.01
- DVA 0.38
- Stochastic Oscillator
- PSO 38.32
- DVA 56.23
About PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.